Stock events for Arcutis Biotherapeutics, Inc. (ARQT)
Arcutis Biotherapeutics' stock price has been impacted by several events over the past six months. The company reported strong financial results for Q3 2025, with net product revenue for ZORYVE increasing significantly. ZORYVE cream received FDA approval for atopic dermatitis in children. The company surpassed expectations with its Q4 2025 earnings, achieving positive operating cash flow and revising its 2026 full-year net product sales guidance upward. The stock has seen exceptional returns over the past year and six months, though it has experienced some recent pullbacks. Max Homa joined Arcutis' "Free to Be Me" campaign. Arcutis announced its Fourth Quarter and Full Year 2025 Financial Results and provided a business update. Arcutis began enrolling a Phase 1a/1b study evaluating ARQ-234 in healthy volunteers and adults with atopic dermatitis.
Demand Seasonality affecting Arcutis Biotherapeutics, Inc.’s stock price
Arcutis Biotherapeutics anticipates a typical seasonal reduction in net product revenues during the first quarter of each year due to patient deductible resets. Despite this, the company is confident in ZORYVE's continued growth throughout the rest of the year.
Overview of Arcutis Biotherapeutics, Inc.’s business
Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for dermatological diseases. The company concentrates on chronic inflammatory skin diseases, with its flagship product being ZORYVE® (roflumilast), a PDE4 inhibitor available in cream and foam formulations. ZORYVE cream is indicated for plaque psoriasis and atopic dermatitis, while ZORYVE topical foam is indicated for plaque psoriasis of the scalp and body and seborrheic dermatitis. Arcutis has a pipeline of products in clinical development, including ARQ-255 for alopecia areata, ARQ-252 for chronic hand eczema and vitiligo, and ARQ-234 for atopic dermatitis.
ARQT’s Geographic footprint
Arcutis Biotherapeutics is headquartered in Westlake Village, California, United States. The company plans to expand its presence in international markets, including Europe and Asia.
ARQT Corporate Image Assessment
Arcutis Biotherapeutics has a positive brand reputation, particularly with its product ZORYVE, which is the number one prescribed branded topical therapy across atopic dermatitis, seborrheic dermatitis, and plaque psoriasis combined. Analysts maintain a consensus "Moderate Buy" rating for the stock. The company's commitment to addressing unmet medical needs and improving the quality of life for patients with chronic skin conditions contributes to its positive image. The "Free to Be Me" campaign also enhances brand visibility and patient engagement.
Ownership
Arcutis Biotherapeutics has a diverse ownership structure, including institutional, retail, and individual investors. As of March 3, 2026, the company has 406 institutional owners and shareholders holding a total of 141,744,370 shares. Major institutional owners include Suvretta Capital Management, Llc, Frazier Life Sciences Management, L.P., BlackRock, Inc., Rubric Capital Management LP, Vanguard Group Inc, Jennison Associates Llc, Polar Capital Holdings Plc, State Street Corp, Gilder Gagnon Howe & Co Llc, and Morgan Stanley. Frazier Life Sciences VIII, L.P., BlackRock, Inc., The Vanguard Group, Inc., and State Street Global Advisors, Inc. are also listed as top institutional holders. Rubric Capital Management LP disclosed a 6.75% ownership stake. Patrick Heron owns the most shares among individual investors.
